Tumor site immune markers associated with risk for subsequent basal cell carcinomas

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Glaser, Ronald ^a,b   Andridge, Rebecca ^c   Yang, Eric V ^a,b   Shana'ah, Arwa Y ^a   Di Gregorio, Michael ^a   Chen, Min ^a   Johnson, Sheri L ^d   de Renne, Lawrence A ^a   Lambert, David R ^a   Jewell, Scott D ^a   Bechtel, Mark A ^a   Hearne, Dean W ^a   Herron, Joel Bain ^a   Kiecolt Glaser, Janice K ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 EPSILON ANTIGEN; CD68 ANTIGEN; GAMMA INTERFERON; IMMUNE MARKER; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE ANTIGEN; MESSENGER RNA; TUMOR MARKER; UNCLASSIFIED DRUG; CD3 ANTIGEN; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SKIN CARCINOGENESIS; TUMOR BIOPSY; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CARCINOMA, BASAL CELL; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80053321967     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025160     Document Type: Article

References (35)

1. American Cancer Society (2010) Cancer Facts & Figures 2010. Atlanta American Cancer Society.
2. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, et al. (2010) Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 146: 283-287.
3. Kiiski V, de Vries E, Flohil SC, Bijl MJ, Hofman A, et al. (2010) Risk factors for single and multiple basal cell carcinomas. Arch Dermatol 146: 848-855.
4. Kricker A, Armstrong BK, English DR, (1994) Sun exposure and non-melanocytic skin cancer. Cancer Causes and Control 5: 367-392.
5. Fortina AB, Piaserico S, Caforio ALP, Abeni D, Alaibac M, et al. (2004) Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. Arch Dermatol 140: 1079-1085.
6. Grinyo J, (2010) Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol 6: 511-519.
7. Naldi L, Boschiero L, Nacchia F, Fior F, Forni A, (2010) Incidence and Clinical Predictors of a Subsequent Nonmelanoma Skin Cancer in Solid Organ Transplant Recipients With a First Nonmelanoma Skin Cancer A Multicenter Cohort Study. Arch Dermatol 146: 294-299.
8. Edelbroek J, de Fijter J, Haasnoot G, Claas F, Willemze R, (2010) Subsequent Squamous- and Basal-Cell Carcinomas in Kidney-Transplant Recipients After the First Skin Cancer: Cumulative Incidence and Risk Factors. Transplantation 89: 1231-1238.
9. Halliday GM, Patel A, Hunt MJ, Tefany FJ, Barnetson RS, (1995) Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World J Surg 19: 352-358.
10. Wong DA, Bishop GA, Lowes MA, Cooke B, Barnetson RS, et al. (2000) Cytokine profiles in spontaneously regressing basal cell carcinomas. Brit J Dermatol 143: 91-98.
11. Domingo DS, Baron ED, (2008) Melanoma and nonmelanoma skin cancers and the immune system. Advances in experimental medicine and biology 624: 187-202.
12. Kaur P, Mulvaney M, Carlson JA, (2006) Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis. Am J Dermatopathol 28: 293-307.
13. Hunt MJ, Halliday GM, Weedon D, Cooke BE, Barnetson RS, (1994) Regression in basal cell carcinoma: an immunohistochemical analysis. Brit J Dermatol 130: 1-8.
14. Marcil I, Stern RS, (2000) Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer. Arch Dermatol 136: 1524-1530.
15. Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, et al. (2003) Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 139: 1325-1332.
16. De Giorgi V, Salvini C, Chiarugi A, Paglierani M, Maio V, et al. (2009) In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma. Int J Dermatol 48: 312-321.
17. Schemper M, Smith TL, (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17: 343-346.
18. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
19. Fillenbaum GG, Smyer MA, (1981) The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol 36: 428-434.
20. Schlecker C, Pierer G, Haug M, (2009) Spontaneous regression of two giant basal cell carcinomas in a single patient after incomplete excision. Tumori 95: 258-263.
21. Kim J, Modlin R, Moy R, Dubinett S, McHugh T, et al. (1995) IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 155: 2240-2247.
22. Carlson JA, Combates NJ, Stenn KS, Prouty SM, (2002) Anaplastic neoplasms arising from basal cellcarcinoma xenotransplants into SCID-beige mice. J Cutan Pathol 29: 268-278.
23. Kahn HS, Tatham LM, Patel AV, Thun MJ, Heath CW Jr, (1998) Increased cancer mortality following a history of nonmelanoma skin cancer. JAMA 280: 910-912.
24. Cantwell MM, Murray LJ, Catney D, Donnelly D, Autier P, et al. (2009) Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland. Br J Cancer 100: 174-177.
25. Nugent Z, Demers AA, Wiseman MC, Mihalcioiu C, Kliewer EV, (2005) Risk of second primary cancer and death following a diagnosis of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 14: 2584-2590.
26. Rosenberg CA, Greenland P, Khandekar J, Loar A, Ascensao J, et al. (2004) Association of nonmelanoma skin cancer with second malignancy. Cancer 100: 130-138.
27. Uitto J, (2008) The role of elastin and collagen in cutaneous aging: intrinsic aging versus photoexposure. J Drugs Dermatol 7: s12-16.
28. Kripke ML, (1994) Ultraviolet radiation and immunology: something new under the sun-presidential address. Cancer Res 54: 6102-6105.
29. Slominski A, (2007) A nervous breakdown in the skin: stress and the epidermal barrier. J Clin Invest 117: 3166-3169.
30. Schwarz T, (1999) Ultraviolet radiation-induced tolerance. Allergy 54: 1252-1261.
31. Schwarz A, Maeda A, Wild MK, Kernebeck K, Gross N, et al. (2004) Ultraviolet radiation-induced regulatory T cells not only inhibit the induction but can suppress the effector phase of contact hypersensitivity. J Immunol 172: 1036-1043.
32. Paul J, (2011) Lymphangiectases are common underlying warts and in normal peritumoral skin: histologic evidence of decreased immune surveillance. Am J Dermatopath 33: 152-160.
33. Barnes EA, Heidtman KJ, Donoghue DJ, (2005) Constitutive activation of the shh-ptc1 pathway by a patched1 mutation identified in BCC. Oncogene 24: 902-915.
34. Hutchin ME, Kariapper MST, Grachtchouk M, Wang A, Wei L, et al. (2005) Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev 19: 214-223.
35. Goppner D, Leverkus M, (2011) Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. Journal of Skin Cancer 2011.